Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Myocarditis
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrollment
- 1400
- Locations
- 1
- Primary Endpoint
- Major cardiac events
- Status
- Recruiting
- Last Updated
- 11 months ago
Overview
Brief Summary
The AMPHIBIA study is an observational ambispective and prospective cohort that aim to describe the histologic, immunologic, biological, imaging, genetic and clinical characteristics of the patients hospitalized for an acute myocarditis and to evaluate their association with prognosis.
Detailed Description
Acute myocarditis is an inflammatory disease of the heart muscle. Its clinical presentation and its etiologies are multiple and make it a complex disease to treat. Its course also varies, ranging from complete clinical recovery to recurrence of ventricular arrhythmia or progression to chronic dilated heart disease, while being difficult to predict. The long-term prognosis is poorly understood. Consecutive patients hospitalized in a tertiary university referral center cohort from 2006 to 2041 for an acute myocarditis will be ambispectively or prospectively analyzed. This project will establish a registry including up to 400 patients in the ambispective analysis cohort from 2006 to 2021 and 1000 patients in the prospective analysis cohort during a 20 years inclusion period. The aim of the study is to describe the characteristics of patients hospitalized for an acute myocarditis and to evaluate their association wih the long term (until 20 years) prognosis. Features of interest will include : * Clinical * Biological * Etiological * Echocardiographic * Cardiac magnetic resonance imaging * Genetics (for the prospective cohort) * Anatomopathological The collection of clinical, biological and radiological data will represent an unique source allowing research teams in the coming years to access the data necessary to answer various specific questions (pathophysiological, diagnostic, prognostic) relevant to the state of knowledge on this pathology.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Acute myocarditis confirmed by cardiac magnetic resonance according to Lake Louise modified criteria or by endomyocardial biopsy according to histologic, immunologic and immunohistochemic criteria.
- •affiliation to the French Health Care System "Sécurité sociale"
Exclusion Criteria
- •Severe valvulopathy
- •Complex congenital cardiopathy
- •Previous heart transplant
- •Known significative coronary disease
Outcomes
Primary Outcomes
Major cardiac events
Time Frame: up to 1 years
Defined as a composite of : * All cause death * Resuscitated cardiac arrest * Heart transplant * Longterm mechanical circulatory support * Ventricular arrhythmia after discharge * Hospitalization for heart failure * Hospitalization for myocarditis recurrence
Secondary Outcomes
- Heart transplant(up to 20 years)
- Major cardiac events(up to 20 years)
- Resuscitated cardiac arrest(up to 20 years)
- Longterm mechanical circulatory support(up to 20 years)
- Supra ventricular arrythmia(up to 20 years)
- All cause death(up to 20 years)
- Cardiovascular death(up to 20 years)
- Sustained ventricular arrhythmia after discharge(up to 20 years)
- Hospitalization for myocarditis recurrence(up to 20 years)
- Hospitalization for heart failure(up to 20 years)
- Pericardial drainage(up to 20 years)
- High grade atrioventricular block(up to 20 years)
- Pericarditis(up to 20 years)
- Left ventricular systolic function under 50%(up to 20 years)
- Therapeutics during hospital stay(From the day of admission up to 90 days)